HSIC

Business profile & competitive position

Henry Schein, Inc. is classified in the Healthcare sector, specifically the Medical - Distribution industry. That means the company sits between manufacturers of medical, dental, and veterinary supplies and the offices, clinics, and hospitals that consume them. Its value proposition is therefore logistical—breadth of inventory, delivery reliability, credit and customer service—rather than pharmaceutical discovery or device innovation.

The financial profile that accompanies this model is a 3.0% net margin and a 12.4% return on equity. The 3.0% margin is typical of distribution, where pricing power is limited and scale is the main defense. What matters for competitive moat is whether those thin margins still produce durable returns. With ROE of 12.4%, Henry Schein is earning more on its book equity than most investors would demand as a cost of capital, which points to capital efficiency, steady demand, and possibly some supplier or customer-stickiness advantages. The moat is operational, not proprietary.

Financial posture

As of the August 10, 2026 snapshot, Henry Schein carried a $10.0 billion market capitalization and traded at a P/E of 25.5. Against a net margin of just 3.0%, that multiple suggests the market is paying for stability, recurring revenue, and defensive healthcare exposure rather than for current earnings power alone. A 25.5x P/E is not deep-value territory, but it is also not unusual for a lower-volatility healthcare name.

The stock’s beta of 0.81 underlines that lower-volatility profile: the stock has historically moved less than the broad market, consistent with a distribution model tied to non-discretionary healthcare spending. At a price of $88.08, the stock sat above its 50-day EMA of $83.75, with an RSI of 60.3. That RSI is in neutral-to-firm territory rather than an extreme. ROE of 12.4% reinforces that capital is being reinvested productively. The central question for valuation is whether 25.5x earnings leaves room for any slowdown in volume or margin compression.

Macro & geopolitical exposure

Because Henry Schein is a Medical - Distribution business, its macro exposures are those of the healthcare supply chain rather than of clinical outcomes. Tariffs and trade policy on imported gloves, PPE, dental consumables, and medical instruments directly affect cost of goods sold. FDA and other health-product regulations determine which products can be stocked and how they are sourced. Reimbursement rules for dental, physician, and veterinary procedures influence end-user demand and ordering patterns.

Currency fluctuations matter if products are sourced globally, while freight, fuel, and warehouse costs feed directly into gross margins. Broader healthcare policy—changes to Medicare reimbursement, infection-control standards, or practice economics—can shift how frequently offices order and how price-sensitive they become. Distributors generally cannot raise prices unilaterally, so their risk is operational: passing through cost changes, preserving customer relationships, and maintaining inventory availability during supply shocks.

Recent developments

Henry Schein drew several style-focused headlines from Zacks in early August 2026. On August 5, Zacks published “Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?,” highlighting that the stock had reached a new high. The next day, August 6, Zacks compared Henry Schein with another name in “HSIC or SAUHY: Which Is the Better Value Stock Right Now?.” By August 10, Zacks ran two more pieces: “Should Value Investors Buy Henry Schein (HSIC) Stock?” and “Here's Why Henry Schein (HSIC) is a Strong Momentum Stock.”

This cluster of value and momentum articles landed just after the company’s August 4, 2026 earnings release, when Henry Schein reported actual EPS of $1.27 versus an estimate of $1.24, a 2.4% positive surprise. The stock gained 0.54% the next trading day and showed a null 5-day drift. The sequence illustrates how quickly the narrative around a stock can shift from the numbers themselves to stylistic categorization once fresh price highs and earnings data are in the market.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Henry Schein has beaten earnings estimates six times, a 75% beat rate, with an average surprise of 2.9%. That pattern suggests either conservative guidance, steadily improving execution, or analysts underestimating the resilience of the distribution model.

Yet the post-earnings price response has not consistently rewarded those beats. Across those same eight quarters, the average 5-day price move after earnings was -2.76%, classified as a “down” drift. The last four quarters show the same tension. On May 5, 2026, the company reported actual EPS of $1.32 versus an estimate of $1.20, a 10% surprise, but the stock fell 2.6% the next day and 6.75% over the following five sessions. On February 24, 2026, a 3.1% beat ($1.34 actual versus $1.30 estimate) was followed by a 1.73% next-day drop and a 3.77% five-day decline. The November 4, 2025 report was the exception: a 8.7% beat ($1.38 versus $1.27) produced a 0.56% next-day gain and a 2.25% five-day gain. Most recently, the August 4, 2026 report delivered a 2.4% beat, a 0.54% next-day gain, and a flat five-day move.

The next scheduled report is November 3, 2026, before the market open, with a consensus EPS estimate of $1.35. The historical pattern suggests that even when Henry Schein exceeds the official consensus, the price reaction over the following week has more often leaned negative. That implies the market's real expectation may already be higher than the published estimate, so reported “beats” can still be sold once details are scrutinized.

For a deeper perspective on how sell-side and institutional models are interpreting these figures, readers should review the full institutional verdict on Henry Schein, which aggregates analyst ratings, target ranges, and fundamental assumptions beyond the raw numbers.